EnergieShake® Acceptability and Tolerance Study
Open Label Study of Acceptability, Tolerance, and Compliance Using EnergieShake® Dietary Powdered Supplement
1 other identifier
interventional
18
1 country
1
Brief Summary
This open-label, prospective, controlled intervention study involves evaluating tolerance and acceptability of an Oral Nutrition Supplement (ONS; EnergieShake®) in 16 adult patients who are already taking an ONS. Following a 2-day baseline data collection on their current ONS, patients switch to the test ONS, which is taken for a further 8 consecutive days. Patients revert to their current ONS at the end of the study. Patients act as their own controls and thus all patients are allocated the same intervention. Daily records of GI tolerance and compliance with the prescribed amount of ONS will be kept for participants throughout the study period. Participants' height and weight will be collected at baseline (weight at end will also be collected), all medications will be documented, and relevant medical and dietary histories will be recorded. A questionnaire at the end of the intervention period will be administered collecting participants' views on the acceptability (taste and palatability) of the test ONS. Taste and palatability will be assessed via a questionnaire that uses a Hedonic scale to quantify preference.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jul 2016
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 24, 2016
CompletedFirst Posted
Study publicly available on registry
June 2, 2016
CompletedStudy Start
First participant enrolled
July 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2016
CompletedJune 2, 2016
May 1, 2016
Same day
May 24, 2016
June 1, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Tolerance: how well the participant tolerates the Oral Nutritional Supplement, including changes to gastrointestinal symptoms.
The primary objective of the study is to assess gastrointestinal (GI) tolerance (bowel frequency and consistency using the Bristol Stool Chart, nausea, vomiting, abdominal discomfort, wind, burping, flatulence) to test Oral Nutrition Supplement (EnergieShake®, a powdered nutritional supplement, classified as a Food for Special Medical Purposes for the dietary management of disease-related malnutrition) in patients requiring ONS.
10 days
Secondary Outcomes (1)
How acceptable the Oral Nutritional Supplement is to the participant, (taste, texture, aroma, consistency, etc.) Compliance with Oral Nutritional Supplement.
10 days
Study Arms (1)
EnergieShake Intervention
OTHERSingle arm of intervention of Oral Nutritional Supplement in the open label study to be given to participants for 8 days Two 57g sachets of EnergieShake daily to be given to participants during the 8 day intervention period.
Interventions
The participants will be given EnergieShake® powdered nutritional supplement twice daily during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days followed by an 8 day intervention on EnergieShake®
Eligibility Criteria
You may qualify if:
- Adult (18 years or older)
- Participants with or at risk of malnutrition who are already taking ONS on a daily basis
- Participants expected to continue to require ONS for at least a further 2 weeks
- Participants able to give their informed consent to participate
You may not qualify if:
- Requirement of tube or parenteral nutrition.
- Participants receiving palliative care.
- Participants with chronic renal disease or liver failure.
- Participants requiring a milk/lactose free diet
- Participants with significant on-going gastrointestinal symptoms.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fermoyle Nursing Home
London, Surrey, KT15 1SH, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ryan Rodrigues, Masters
Anaiah Healthcare Ltd
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 24, 2016
First Posted
June 2, 2016
Study Start
July 1, 2016
Primary Completion
July 1, 2016
Study Completion
July 1, 2016
Last Updated
June 2, 2016
Record last verified: 2016-05
Data Sharing
- IPD Sharing
- Will not share